A student-run resource for reliable reports on the latest law and technology news

Archive for the ‘Pharmaceuticals’ Category

The Way the Cookie Crumbles: “Metaphorical” Arguments Before The Supreme Court on the Patentability of Genes

Ass’n for Molecular Pathology v. Myriad Genetics, Inc.
By Alex Shank – Edited by David LeRay

On Monday, April 15, the Supreme Court heard oral arguments to determine the validity of a patent encompassing the use of the BRCA1 and BRCA2 genes. Mutations in these genes correlate strongly with the development of breast and ovarian cancers. As the patent owner, Myriad Genetics, Inc. (“Myriad”) possesses and exercises the exclusive right to sell diagnostic testing kits based on these genes.

Read More...

Posted On Apr - 29 - 2013 Comments Off READ FULL POST

Supreme Court Hears Oral Arguments on Reverse Payments to Generic Drug Manufacturers

FTC v. Actavis, Inc.
By Suzanne Van Arsdale – Edited by Jennifer Wong

On Monday, March 25, the Supreme Court heard oral arguments in FTC v. Actavis, Inc., to determine the legality, under antitrust laws, of patent litigation settlements made by the maker of a brand-name drug to the maker of a generic competitor to keep the generic off the market temporarily, known as a “reverse payment agreement” or “pay for delay.”

Read More...

Posted On Apr - 3 - 2013 Comments Off READ FULL POST
Third Circuit Subjects Reverse Payments to Strict Antitrust Scrutiny By Jie Zhang – Edited by Charlie Stiernberg In Re: K-Dur Antitrust Litigation, No. 10-2077 (3d Cir. July 16, 2012) Slip opinion The Third Circuit Court of Appeals reversed the summary judgment of the United States District Court for the District of New Jersey, which had rejected an antitrust challenge to a reverse payment agreement between the K-Dur patent holder Schering-Plough Corporation (“Schering”) and the generic drug manufacturer Upsher-Smith Laboratories (“Upsher”) ... Read More...
Posted On Aug - 7 - 2012 Comments Off READ FULL POST
Written By: Sally Wang Edited By: Charlie Stiernberg Editorial Policy Introduction: Drug marketing faces the problem of an arms race — competitors attempt to out-compete each other by boosting their marketing efforts, at great expense, only to find that the baseline level of marketing needed to maintain the status quo has increased accordingly. These inefficiencies are costly and often harmful to the stakeholders — drug companies, patients, payors (e.g., Medicare/Medicaid or health insurance companies) and physicians. The Food and Drug Administration (“FDA”) is in ... Read More...
Posted On May - 25 - 2012 Comments Off READ FULL POST
Supreme Court Expands Generic Drug Manufacturers’  Right to Challenge Scope of Patents By Elettra Bietti – Edited by Lauren Henry Caraco Pharmaceutical Laboratories, Ltd. v Novo Nordisk A/S, No. 10–844 (U.S. April 17, 2012) Slip opinion The Supreme Court reversed the Federal Circuit Court of Appeals’ ruling that denied a generic manufacturer the right to compel a brand manufacturer to correct misstatements regarding uses covered by a patent when those corrections would have allowed the generic manufacturer to market their ... Read More...
Posted On Apr - 23 - 2012 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Photo By: archie4oz - CC BY 2.0

European Court of Ju

By Paul Klein – Edited by Alex Shank [caption id="attachment_4363" align="alignleft" ...

Photo By: Kyle Nishioka - CC BY 2.0

Google to Supreme Co

By Michael Shammas – Edited by Mary Schnoor [caption id="attachment_4353" align="alignleft" ...

Photo By: Mozilla in Europe - CC BY 2.0

Mozilla Announces Re

By Sheri Pan – Edited by Corey Omer [caption id="attachment_4341" align="alignleft" ...

Icon-news

Flash Digest: News I

By Emma Winer Third Circuit Vacates Hacker Conviction for Improper Venue The ...

Photo By: Yuri Samoilov - CC BY 2.0

Supreme Court Weighs

By Mary Schnoor — Edited by Elise Young [caption id="attachment_4322" align="alignleft" ...